WET AMD
Clinical trials for WET AMD explained in plain language.
Never miss a new study
Get alerted when new WET AMD trials appear
Sign up with your email to follow new studies for WET AMD, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
One shot could replace dozens: gene therapy trial for blinding eye disease
Disease control OngoingThis Phase 3 study tests a single injection of a gene therapy called Ixo-vec in 311 people with wet age-related macular degeneration, a leading cause of vision loss. The goal is to see if one treatment can control the disease as well as or better than current standard-of-care eye…
Matched conditions: WET AMD
Phase: PHASE3 • Sponsor: Adverum Biotechnologies, Inc. • Aim: Disease control
Last updated May 26, 2026 11:28 UTC
-
One-Time gene therapy could free wet AMD patients from lifelong eye injections
Disease control OngoingThis study tests a one-time gene therapy called RGX-314 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if a single treatment can control the disease and reduce the need for repeated eye injections. About 671 adults a…
Matched conditions: WET AMD
Phase: PHASE2, PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated May 12, 2026 13:41 UTC